AlphAIAlphAI — Financial news for AI agents
investing.comOCT 262 min read$CORT

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

Original reporting
investing.com
Published Oct 26, 2026, 12:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CORT
Bullish
high confidence
Mentioned
$CORT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CORTBullishHigh
01

Why it matters

Positive Phase 2 data may accelerate discussions with regulators and partners, supporting a higher valuation.

02

Market read

First report of meaningful efficacy data for a late‑stage ovarian‑cancer trial, driving a pre‑market rally.

03

What to watch

Competitive pressure from Genmab's RAINFOL‑02 trial and the need for larger Phase 3 confirmation.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Corcept Therapeutics (CORT) focuses on glucocorticoid receptor antagonists for endocrine‑related cancers. The BELLA trial evaluates its lead candidate relacorilant in a triple‑drug regimen.

Company-level read

Ticker impact

$CORTBullishHigh confidence
Context

Corcept Therapeutics reported positive Phase 2 BELLA trial data showing 7.2 months median PFS and 59% response rate for the Lifyorli + nab-paclitaxel + bevacizumab combo.

Expected impact

upward pressure as the market prices in the efficacy data and potential label expansion.

Evidence & confidence

First disclosure of Phase 2 data with clear numerical improvements over prior regimen; market reaction already visible in pre‑open price.

Market effects

Sector

May boost sentiment for the ovarian‑cancer biotech niche and related oncology pipelines.

Regional

Primarily U.S. biotech market; limited immediate effect on broader indices.

Global

Potential interest from global investors tracking oncology trial outcomes.

Counterpoint

What could challenge this read

If the data fails to translate into regulatory approval or commercial uptake, the rally could be short‑lived.

Key entities

  • company
    Corcept Therapeutics

    Biotech firm developing relacorilant for oncology indications.

  • company
    Genmab

    Competitor with a Phase 3 trial in the same patient population.

Read at source← All news

StoryCorcept Therapeutics reports positive Phase 2 BELLA trial results for Lifyorli in platinum‑resistant ovarian cancer

Related articles

OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min
SEP 19
$CORTHighAI 8/10

CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally

Corcept Therapeutics (CORT) shares rose 7% to their highest 2026 levels after announcing plans to resubmit its NDA for Relacorilant, a Cushing’s syndrome treatment, following positive FDA discussions. The FDA rejected the initial filing in December, citing insufficient effectiveness data. The company expects a PDUFA date six months post-submission. CORT shares are down 27% year-to-date, with retail sentiment remaining bearish.

stocktwits.com2 min